First Sound Pharmaceuticals has welcomed two key products in the third quarter

, according to the announcement of the Hong Kong Stock Exchange, the sound medicine industry has recently been heard through the Hong Kong Stock Exchange. Synx Pharmaceuticals filed an IPO application on the Hong Kong Stock Exchange in June this year, in accordance with Article 8.12 of the Listing Rules. According to the hearing information set, the funds raised on the HKEx will be used in part for the ongoing research and development of selected products in the field of oncology and the central nervous system. It's worth noting that in the third quarter of this year, the acoustics industry welcomed two key products, Idala's rightol injection with a strong solution and a basip.Synth Pharmaceuticals is a pharmaceutical company that is rapidly transforming into an innovation and research and development driver, dedicated to making more effective drugs possible for patients. In 2000, the First Sound New Drug Research Center was established. In 2003, the Synth Pharmaceutical Research Institute was established, and in 2018, the Synth Pharmaceutical Innovation Center was established. The company focuses on three fast-growing therapeutic areas with significant unsupered medical needs, including tumors, central nervous system diseases, and autoimmune diseases. According to publicly available information on Synth Pharmaceuticals, it currently has more than 50 product portfolios, most of which are in the national health insurance and national essential medicines catalogues.One after another ushered in key productsamong the listed products, Class 1 innovative drug Endo (recombinant human endodermic inhibitor injection), is one of the earliest antivascular targeted drugs listed in China. The autoimmune disease treatment drug Edsin (Iramod tablets) has been recommended by several guidelines as the main treatment for active rheumatoid arthritis. Both new drugs will be included in the National Health Insurance Drug List from 2017.In the third quarter of this year, the first sound medicine industry ushered in two key products. These include the company's 13 years of independent research and development with independent intellectual property rights of a class 1 innovative drug Ida Lafeng rightalcohol injection with a thick solution, approved in China through the priority review process, adaptive disease for stroke patients.Another A basip injection, developed by BMS, was officially launched in China in August for rheumatoid arthritis. This is a soluble fusion protein formed by the fusion of human cytotoxic T lymphocyte-related antigen 4 (CTLA-4) extracellular region with human IgG1Fc region. In 2013, BMS reached a strategic partnership with Synth Pharmaceuticals to develop Abrasip in China.In addition, according to the hearing data set, the recent acoustic pharmaceutical industry is also expected to usher in a subdermal injection of PD-L1 monoantigen KN035 (envafolimab). In March 2020, Synth Pharmaceuticals signed a cooperation agreement with Jiangsu Corning Jerry and Beijing Yidi Pharmaceuticals, which grants Synsheng Pharmaceuticals exclusive rights to market and promote KN035 in China for all tumor adaptations. Currently, the product is in phase 2 clinical trials for colorectal cancer and other advanced solid tumors, as well as Phase 3 clinical trials for advanced bilial cancer, and is expected to be approved for market in 2021. It is worth mentioning that the product was included in the priority review list in China in September this year on the grounds that it "meets the conditions for approval of the drug". (
medicine Mingkangde
)